Galenica Ag · SIX:GALE
Galenica — Investor Presentation (March 2022)
90 slides from Galenica's investor presentation, March 2022
Slide 1: Galenica Group Investor Presentation
Galenica Group Investor Presentation March 2022 Galenica – Health and wellbeing are at the heart of what we do. C1 - Internal
Slide 2: Table of contents
About Galenica Market environment Business performance Governance Sustainability Outlook Table of contents 3 About Galenica 28 Market environment 41 Business performance 62 Governance 72 Sustainability 81 Outlook 21/04/22 2 C1 - Internal
Slide 3: About Galenica
About Galenica Galenica – Health and wellbeing are at the heart of what we do. 3 C1 - Internal
Slide 4: Galenica in figures
About Galenica Market environment Business performance Governance Sustainability Outlook Galenica in figures Net sales EBIT adjusted1) Leading healthcare Employees provider in Switzerland (Headcount) in million CHF in million CHF 368 own pharmacies > 7,200 Galenica Group Galenica Group Debt coverage
Slide 5: Building the leading Swiss healthcare platform over 90 years
About Galenica Market environment Business performance Governance Sustainability Outlook Building the leading Swiss healthcare platform over 90 years Foundation of Joint IPO Acquisition Galenica as a Venture wholesaler Acquisition Strategy to Acquisition engage in the entire Swiss Acquisition Creati
Slide 6: Switzerland's leading fully integrated healthcare provider
About Galenica Market environment Business performance Governance Sustainability Outlook Switzerland's leading fully integrated healthcare provider Largest network of Wide range of services for pharmacies in Switzerland patients and professional with over 500 pharmacies, service providers online and
Slide 7: Customer promise
About Galenica Market environment Business performance Governance Sustainability Outlook Customer promise We support people at every stage of life on their journey towards health and well-being. With personal and expert advice and a unique range of products and services. Anytime and anywhere in Swit
Slide 8: What we do
About Galenica Market environment Business performance Governance Sustainability Outlook What we do Vision Health and wellbeing are at the heart of what we do. They are the reason we give our best every day. Values We build We show Together, we We act as We participate with trust respect are stronge
Slide 9: Business model
About Galenica Market environment Business performance Governance Sustainability Outlook Business model Vision Customer promise Health and wellbeing are at the We support people at every stage of life on their heart of what we do. They are the journey towards health and wellbeing. reason we give our
Slide 10: Strategic programmes
About Galenica Market environment Business performance Governance Sustainability Outlook Strategic programmes Market orientation Internal organisation Omni-Channel Care Professionals Efficiency Transformation − Best customer experience − First point of contact for − First-choice partner for − Simple
Slide 11: Our Business Units: Strong on the market
About Galenica Market environment Business performance Governance Sustainability Outlook Our Business Units: Strong on the market Products & Care Logistics & IT Retail (B2C) Professionals (B2B) Local Pharmacies Pharmacies at Home Products & Brands Services for Wholesale Logistics & Professionals IT
Slide 12: Our Business Areas
About Galenica Market environment Business performance Governance Sustainability Outlook Our Business Areas Net sales EBIT 1 in million CHF in million CHF 3,835 213 Products & Care Logistics & IT Net sales EBIT 1 Net sales EBIT 1 in million CHF in million CHF in million CHF in million CHF 1,908 154
Slide 13: Local pharmacies: Three largest pharmacy chains in Switzerland
About Galenica Market environment Business performance Governance Sustainability Outlook Local pharmacies: Three largest pharmacy chains in Switzerland Key takeaways Largest branded pharmacy network by number of pharmacies − Largest pharmacy network offers broad product in Switzerland 1 range, inclu
Slide 14: Local pharmacies: Broad range of product and service offerings
About Galenica Market environment Business performance Governance Sustainability Outlook Local pharmacies: Broad range of product and service offerings Amavita and Sun Store product offering Service offerings in local pharmacies in % of sales1 (selection) Primary Care Health Checks Prescription medi
Slide 15: Local pharmacies: Always available where our customers are
About Galenica Market environment Business performance Governance Sustainability Outlook Local pharmacies: Always available where our customers are Widely spread pharmacy network covers every Demonstrated M&A track record with an average of Region in Switzerland 9 pharmacies acquired and 8 net pharm
Slide 16: Pharmacies at home: Mail order pharmacies and home care services
About Galenica Market environment Business performance Governance Sustainability Outlook Pharmacies at home: Mail order pharmacies and home care services Key takeaways Total Retail Net Sales − Business area covers both home care (Bichsel & Mediservice) and Mail-order pharmacies (Mediservice & websho
Slide 17: Pharmacies at home: Bichsel home care services
About Galenica Market environment Business performance Governance Sustainability Outlook Pharmacies at home: Bichsel home care services for over 9,000 active patients across Switzerland − Improve quality of life, e.g. enhanced mobility, continuation in familiar setting − Efficient provision of servi
Slide 18: Pharmacies at home: Mediservice market leading mail-order pharmacy
About Galenica Market environment Business performance Governance Sustainability Outlook Pharmacies at home: Mediservice as market leading Mail-order pharmacy in Switzerland1 Market leading mail-order Market Share Mail-order pharmacies1 pharmacy in Switzerland1 70% Specialty pharmacy focused on pati
Slide 19: Products & Brands: Strong brands for the Swiss Consumer Healthcare Market
About Galenica Market environment Business performance Governance Sustainability Outlook Products & Brands: Strong brands for the Swiss Consumer Healthcare Market Key takeaways − Leading position1) in the Swiss consumer healthcare market (CHC) Selected − Preferred Consumer Health partner for Swiss o
Slide 20: Products & Brands: Verfora market share in Swiss CHC market
About Galenica Market environment Business performance Governance Sustainability Outlook Products & Brands: Strong brands for the Swiss Consumer Healthcare Market Verfora market share in Swiss CHC market1 Market share of main OTC product categories of Verfora OTC products 11.4% market share CHF 181.
Slide 21: Products & Brands: Proven M&A track record
About Galenica Market environment Business performance Governance Sustainability Outlook Products & Brands: Proven M&A track record as key driver for market share growth Verfora growth strategy − Big OTC brands Acquisition Acquisition Hedoga Group Dr. Wild − Emerging platforms Distribution 10.0% com
Slide 22: Services for Professionals
About Galenica Market environment Business performance Governance Sustainability Outlook Services for Professionals: We support healthcare professionals with high quality services − Lifestage Solutions develops and operates a fully integrated digital trading platform for home care organisations and
Slide 23: Wholesale: Leader in wholesale distribution
About Galenica Market environment Business performance Governance Sustainability Outlook Wholesale: Leader in wholesale distribution Key takeaways Wholesale market share1 − Wide product range with around 100,000 % pharmacy channel Galenica products in pharma, non-pharma, (to own 25.2 pharmacies) pra
Slide 24: Wholesale: Distribution centers and customers by channel
About Galenica Market environment Business performance Governance Sustainability Outlook Wholesale: Leader1) in wholesale distribution Wholesale distribution with four distribution centers: Customers by channel Pharmacies ~ 1,250 Basel Widnau Zürich Niederbipp Drugstore ~ 250 Neuenburg Luzern Bern C
Slide 25: Logistics & IT Services: Leader in pre-wholesale distribution
About Galenica Market environment Business performance Governance Sustainability Outlook Logistics & IT Services: Leader in pre-wholesale distribution Key takeaways Warehouse capacity − Third-party logistics provider for the pharmaceutical industry 35,200 m2 (pre-wholesaling) including additional se
Slide 26: Logistics & IT Services: Strong IT competencies
About Galenica Market environment Business performance Governance Sustainability Outlook Logistics & IT Services: Strong IT competencies to drive digital transformation Key takeaways − Agile Software Development and Projects for Galenica pharmacies und Logistic platforms. Internal IT Services Market
Slide 27: Logistics & IT Services: Patient safety, convenience and efficiency
About Galenica Market environment Business performance Governance Sustainability Outlook Logistics & IT Services: Our approach towards more patient safety, convenience and efficiency Medication Master Data Diagnosis Clinical Decision Support (CDS) Anamnesis Prescription Patients on-/offline e-Prescr
Slide 28: Market environment
Market environment Galenica – Health and wellbeing are at the heart of what we do. C1 - Internal
Slide 29: Swiss healthcare market: resilient and stable growth
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss healthcare market Proven track record of resilient and stable growth Development of Swiss healthcare retail sector1 in billion CHF (based on ex-manufacturer price) 2020-25 CAGR 2.0%3 6 2011-20 CAGR 2.2%2 5
Slide 30: Swiss pharmaceutical market: Development by channel 2021
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss pharmaceutical market: Development by channel 2021 Value (ex-factory): CHF 6‘619.3 million Volume (packs): 181.8 million CHF +281.7 million / +4.4% -1.1 million / -0.6% Pharmacies 8.8% Pharmacies CHF 3,174
Slide 31: Swiss pharmaceutical market: monthly development 2019-2021
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss pharmaceutical market: monthly development 2019 - 2021 Strong sales increase in past two month of 2021 in million CHF Source: APO/SD/DRO/SPI Index, Swissmedic A, B, C, D Medicines Swissmedic lists A, B, D,
Slide 32: Galenica as key driver of generic substitution
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss pharmaceutical market: Galenica as key driver of generic substitution in the Swiss pharmacy channel Drugs reimbursable by health insurance Patent protected products Substitution rate market3 4.8 million, +
Slide 33: Consumer healthcare market: Normalisation of OTC sales
About Galenica Market environment Business performance Governance Sustainability Outlook Consumer healthcare market: Normalisation of sales of OTC medications in H2 2021 Consumer healthcare market 2021 (w/o COVID-19 self-tests) OTC Market development 3.5% –0.5% of Verfora products (OTC) 12.9% Person
Slide 34: Swiss Healthcare Market: Regulatory environment
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss Healthcare Market: Regulatory environment Topic / Initiative Current status Reduction in drug − Standard process, FOPH verifies drug prices in a three-year cycle prices − Price reduction round for 2021 com
Slide 35: Regulatory environment: Constant pressure on drug prices
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss healthcare market: regulatory environment Constant pressure on drug prices Annual savings per channel at public and ex-factory price in million CHF Price reduction rounds 250.0 Pharmacies Physicians Hospit
Slide 36: Current composition of drug prices (SBR IV)
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss healthcare market: regulatory environment Current composition of drug prices (SBR IV) Fixed margin elements help to offset price reductions Composition of the price of a prescription/ reimbursable drug: c.
Slide 37: Proposal of SBR V contract and distribution margin model
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss healthcare market: regulatory environment Proposal of SBR V contract and distribution margin model Price-related surcharge = 3% Surcharge per pack = CHF 9.45 SBR IV SBR V Product margin cap = CHF 300.– ser
Slide 38: New proposal for distribution margin
About Galenica Market environment Business performance Governance Sustainability Outlook Swiss healthcare market: regulatory environment New proposal for distribution margin The new proposal by the FOPH includes an adjustment of the distribution margin model with uniform margin for medications with
Slide 39: Megatrends and their impact on Galenica
About Galenica Market environment Business performance Governance Sustainability Outlook Megatrends and their impact on Galenica Changing customer needs Digitalisation Ageing society We further improve the customer experience We want to play a leading role in the Our strategic focus includes service
Slide 40: COVID-19
About Galenica Market environment Business performance Governance Sustainability Outlook COVID-19 Employees / Company / Initiatives for Business success / Customer behaviour Federal COVID-19 vaccination and Finance measures testing − Working from home, − Galenica made a key − 230,000 antigen, PCR −
Slide 41: Business performance
Our success story Business performance Galenica – Health and wellbeing are at the heart of what we do. C1 - Internal
Slide 42: Target achievement: guidance vs. performance
About Galenica Market environment Business performance Governance Sustainability Outlook Target achievement: guidance vs. performance Guidance 2021 Guidance 2021 Guidance 2021 (March) (Update June) (Update August) Performance 2021 Guidance 2022 Comment Growth between Growth between Growth between At
Slide 43: Key business events 2021
About Galenica Market environment Business performance Governance Sustainability Outlook Key business events 2021 Jan Feb Mar Apr May Jun Expansion of the mail- Introduction of G-Net Roll-out of new ERP Distributions of self-tests Verfora acquires pharma Remote working policy order pharmacy service
Slide 44: Performance overview: resilient growth and margin improvement
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group History of resilient growth and margin improvement Logistics, HealthCare Galenica Information & Retail1 2012 – 2021 CAGRs Retail market sales2 2.7% Galenica net sales 4.1% Gal
Slide 45: Strong performance development in both segments
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Strong performance development in both segments Products & Care Logistics & IT Retail Products & Care1 Logistics and HCI Logistics & IT1 3.4% 5.2% 0.7% 3.9% Net sales (CHFm) 2
Slide 46: Strong sales and EBIT growth
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Strong sales and EBIT growth Net sales (in million CHF) Adjusted2) EBIT (in million CHF) ROS (in %) +10.2% +26.4% 213.1 3’835 3’480 +7.9% 5.6% +24.4% 168.6 2’831 154.5 +13.4%
Slide 47: Adjusted consolidated statement of income
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Adjusted consolidated statement of income1 in million CHF 2021 2020 in % Net sales 3’835 3’480 +10.2% Strong net sales growth of 10.2% Other income 22 15 +44.0% Cost of goods
Slide 48: Solid balance sheet with strong equity ratio
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Solid balance sheet with strong equity ratio in million CHF 1,206 1,110 1,053 Increase of equity due to high net profit Shareholders’ equity adjusted 1) Net debt adjusted 1) D
Slide 49: Condensed balance sheet
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Condensed balance sheet in million CHF Dec 2021 Dec 2020 Change Exceptionally low inventory level Cash and cash equivalents 165 60 +105 due to strong sales in December Trade a
Slide 50: Investments
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Investments in million CHF 60.4 57.0 53.0 18.2 Investments in intangible assets: 20.5 − SAP implementation at Alloga/Galexis 18.9 − digital infrastructure at Galenica related
Slide 51: Strong operating cash flow
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Strong operating cash flow in million CHF 2021 2020 Change Cash flow from operating activities before 281.4 238.8 +42.6 Cash contribution from working capital changes strong o
Slide 52: Sales growth in all business areas
About Galenica Market environment Business performance Governance Sustainability Outlook Performance overview Galenica Group Sales growth in all business areas COVID-19 Net sales (in million CHF) 2021 2020 change Initiatives Local Pharmacies 1’262 1’163 +8.5% +3.1% Pharmacies at Home 459 355 +29.2%
Slide 53: Retail (B2C) – Local Pharmacies
About Galenica Market environment Business performance Governance Sustainability Outlook Segment Products & Care Retail (B2C) – Local Pharmacies Net sales (in million CHF) +8.5% Positive impact of COVID-19 Initiatives 4) +9.6% +7.5% 1’163 1’262 +5.6% 563 600 617 645 Sales at high H1 H2 2020 H1 H2 20
Slide 54: Retail (B2C) – Pharmacies at home
About Galenica Market environment Business performance Governance Sustainability Outlook Segment Products & Care Retail (B2C) – Pharmacies at home Net sales (in million CHF) +29.2% Online sales 4) +50% +27.6% +30.9% 459 355 Additional 218 241 sales in the area of 166 189 rare diseases H1 H2 2020 H1
Slide 55: Professionals (B2B) – Products & Brands
About Galenica Market environment Business performance Governance Sustainability Outlook Segment Products & Care Professionals (B2B) – Products & Brands Net sales (in million CHF) Main new products +17.8% 132 112 27 +12.4% +26.1% 24 +9.1% International 72 55 57 60 Swiss market 14 13 11 13 104 +19.3%
Slide 56: Professionals (B2B) – Services for Professionals
About Galenica Market environment Business performance Governance Sustainability Outlook Segment Products & Care Professionals (B2B) – Services for Professionals Net sales (in million CHF) +1.4% Acquisition of Lifestage Solutions AG in July 2021 +4.0% -1.5% 62 62 Strong sales increase of Medifilm 29
Slide 57: Wholesale: further gains in market share with physicians
About Galenica Market environment Business performance Governance Sustainability Outlook Segment Logistics & IT Wholesale: further gains in market share with physicians Net sales (in million CHF) +7.8% 2’728 2’530 761 +9.8% Positive impact 693 of COVID-19 +8.2% Initiatives 2) Physici ans +7.4% 1’237
Slide 58: Logistics & IT Services
About Galenica Market environment Business performance Governance Sustainability Outlook Segment Logistics & IT Logistics & IT Services Net sales (in million CHF) +13.7% Change in the billing of group-internal IT services due to the new +22.7% organization structure +4.4% 112 98 61 48 50 51 Sales gr
Slide 59: Share information: History of share price since IPO
About Galenica Market environment Business performance Governance Sustainability Outlook Share information History of share price since IPO IPO offer price CHF 39.00 Initial trade price 7 April 2017 CHF 43.00 Share price 31 Dec 2021 CHF 68.55 21/04/22 59 C1 - Internal
Slide 60: Historical dividend per share and dividend yield
About Galenica Market environment Business performance Governance Sustainability Outlook Share information Historical dividend per share and dividend yield2 3.9% Dividend guidance: • Dividend of CHF 2.10 per 3.3% share proposed to AGM 3.0% 3.1% 3.1% on 12 May 2022 • 50% of dividend payout from reser
Slide 61: Share information: Key figures
About Galenica Market environment Business performance Governance Sustainability Outlook Share information Key figures in CHF 2021 2020 Share price at reporting date 68.55 59.00 Highest share price for the year 73.15 72.25 Lowest share price for the year 57.20 57.15 Market capitalisation at reportin
Slide 62: Governance
Governance Galenica – Health and wellbeing are at the heart of what we do. C1 - Internal
Slide 63: Shareholder structure
About Galenica Market environment Business performance Governance Sustainability Outlook Shareholder structure Major shareholders (31 Dec 2021) Proportion of shareholders by country (Dec 2021) − Shareholders over 3%: in % 1% Number of Shareholders Shares in % shares UBS Fund Management 31% Switzerla
Slide 64: Overview of our governance structure and instruments
About Galenica Market environment Business performance Governance Sustainability Outlook Overview of our governance structure and instruments Annual General Meeting External advisory and inspection bodies / auditors Board of Directors Audit and Remuneration Governance, Nomination and Sustainability
Slide 65: Board of Directors
About Galenica Market environment Business performance Governance Sustainability Outlook Board of Directors Daniela − Elected since 2017 Prof. − Elected since 2017 Bosshardt − Pharmacist, Federal Diploma in Pharmacy, Hon. − Swiss-registered Doctor of Internal Medicine and Federal Institute of Techno
Slide 66: Board of Directors: Committees and competencies
About Galenica Market environment Business performance Governance Sustainability Outlook Board of Directors Committees and competencies ARC (Audit and Risk Members: Markus Neuhaus (Chairman), Budget / medium-term planning Bertrand Jungo, Andreas Walde Committee) Risk management Compliance / internal
Slide 67: Board of Directors: Competencies and diversity
About Galenica Market environment Business performance Governance Sustainability Outlook Board of Directors Competencies and diversity Competencies Age of BoD members (Dec 2021) Bosshardt Bruderer Burnier Jungo Neuhaus Walde Daniela Pascale Michel Bertrand Markus Andreas 17% 16% 40 - 45 Industry 45
Slide 68: Management structure Galenica Group
About Galenica Market environment Business performance Governance Sustainability Outlook Management structure Galenica Group 1) Pharmacies* Healthcare* Products & Marketing* Wholecare & Logistics* IT & Digital Services* Virginie Pache Jeschka Daniela Madonna Thomas Szuran Andreas Koch Lukas Ackerman
Slide 69: Executive Committee
About Galenica Market environment Business performance Governance Sustainability Outlook Executive Committee Marc Werner − CEO since 2020 Thomas − Chief Products & Marketing Officer since 2021 CEO − 25 years industry experience Szuran − 25 years industry experience of which 3 years − Joined Galenica
Slide 70: Remuneration
About Galenica Market environment Business performance Governance Sustainability Outlook Remuneration Responsibility for the remuneration process Level of authority CEO Remuneration Committee Board of Directors Annual General Meeting consultative vote on the Remuneration policy proposes approves Rem
Slide 71: Remuneration
About Galenica Market environment Business performance Governance Sustainability Outlook Remuneration Remuneration components STI LTI − The remuneration components of the Corporate Executive 25% individual 50% Committee (EC) consists of a fixed compensation, benefits and objectives average a variabl
Slide 72: Sustainability
Sustainability Galenica – Health and wellbeing are at the heart of what we do. C1 - Internal
Slide 73: Sustainability at Galenica: Overview
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Overview Sustainability guidelines Enterprise value Employees Resource efficiency Long-term increase in the value of Commitment of employees to act The respectful and efficient use of
Slide 74: Sustainability at Galenica: Matrix of the main topics
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Matrix of the main topics 21/04/22 74 C1 - Internal
Slide 75: Our focus areas for sustainable business practice
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Our focus areas for sustainable business practice Corporate governance Patients − Ethical and legal business activities − Increase patient safety and health − Protect patient data and
Slide 76: Our sustainability goals: Corporate governance
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Our sustainability goals Corporate governance Performance 2021 Ethical and legal business activities We train all employees in compliance at least once a year. IT security trainings in
Slide 77: Our sustainability goals: Patients
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Our sustainability goals Patients Performance 2021 Increase patient safety and health − We will expand the use of the e-Mediplan in Galenica Average availability of Amount of Primary C
Slide 78: Our sustainability goals: Environment
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Our sustainability goals Performance 2021 Environment Reduce and safely dispose of waste We will reduce our municipal waste by 50% by 2025. Minimise greenhouse gas emissions − From 202
Slide 79: Our sustainability goals: Employees
About Galenica Market environment Business performance Governance Sustainability Outlook Sustainability at Galenica Our sustainability goals Employees Performance 2021 Promote employee motivation and development Employee motivation rate We will increase the motivation rate of our employee survey to
Slide 80: ESG Ratings
About Galenica Market environment Business performance Governance Sustainability Outlook ESG Ratings Rating-Agentur Rating 2021 Percentile Comment ESG Risk Top 2% (Global Universe) − Ranking number 5 among 605 Healthcare companies − Very good scores in Business ethics, Data NEGL LOW MED HIGH SEVERE
Slide 81: Outlook
Outlook Galenica – Health and wellbeing are at the heart of what we do. C1 - Internal
Slide 82: Outlook Products & Care: Priorities 2022
About Galenica Market environment Business performance Governance Sustainability Outlook Outlook Products & Care Winconcept will Intensify Expansion of the launch a new “Primary Care” collaboration Continuous new Sun Store partnership module from between Bichsel, optimisation and store concept to mo
Slide 83: Outlook Logistics & IT: Priorities 2022
About Galenica Market environment Business performance Governance Sustainability Outlook Outlook Logistics & IT Implementation of Galexis: measures to achieve the sustainability goals Alloga: − Roll-out of the new ERP is a top priority “E-prescription” pilot system to be driven Launch of the new ERP
Slide 84: Net Sales guidance 2022
About Galenica Market environment Business performance Governance Sustainability Outlook Net Sales guidance 2022 in million CHF Net sales guidance 2022: 3,835 ≥ 2.9% − Galenica Group net sales 2022 at least 108 on prior year level Assumptions for 2022: − Gradual return to normal of COVID-19 3,835 si
Slide 85: EBIT guidance 2022
About Galenica Market environment Business performance Governance Sustainability Outlook EBIT guidance 2022 in million CHF 213.1 EBIT guidance 2022: +5% to +10% 9.4 − EBIT adjusted1) +5% to +10%, excluding the extraordinary results from the COVID- 25 19 initiatives (CHF 25 million) and the property
Slide 86: Dividend: strong and sustainable dividend increase
About Galenica Market environment Business performance Governance Sustainability Outlook Dividend: strong and sustainable dividend increase 3.1% 3.1% 3.0% +17% 2.101) Dividend guidance 2022: 1.80 1.80 − at least same level as 2021 2019 2020 2021 Dividend yield 2) Dividend per share (in CHF) 1 Accord
Slide 87: Mid-term guidance
About Galenica Market environment Business performance Governance Sustainability Outlook Mid-term guidance − Thanks to − consistent implementation of the strategic programmes and − further expansion and optimisation of the pharmacy network and the Verfora product portfolio, − Galenica plans to grow
Slide 88: Reasons to invest in Galenica
About Galenica Market environment Business performance Governance Sustainability Outlook Reasons to invest in Galenica Unique combination of defensive resilience and significant growth … Defensive resilience History of growth Strategic focus 1. Stable and attractive Swiss 3. Significant operational
Slide 89: Contact information Investor Relations
About Galenica Market environment Business performance Governance Sustainability Outlook Galenica Group - Contact information Investor Relations Felix Burkhard CFO Tel.: +41 58 852 85 29 Julian Fiessinger Head of Investor Relations and Corporate Finance Tel.: +41 58 852 85 37 Mail: investors@galenic
Slide 90: Disclaimer
About Galenica Market environment Business performance Governance Sustainability Outlook Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and